secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-125940
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo reaches FDA alignment on accelerated approval for LX2006; Q3 net loss $29.5M, cash $157M
--------------------------------------------------------------------------------

- FDA agreed on co-primary registrational endpoints (LVMI reduction and frataxin expression) for LX2006 accelerated approval.
- Received RMAT designation for LX2006; completed enrollment in SUNRISE-FA Phase 1/2 (16 patients dosed to date).
- LX2020 PKP2-ACM cohort 1 enrollment completed; initial safety/biodistribution data expected late Q1/Q2 2025.
- Q3 net loss $29.5M ($0.89 per share) vs $20.1M year-ago; R&D $23.4M, G&A $8.1M.
- Cash $157M expected into 2027; Tolga Tanguler (Alnylam exec) appointed to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024125940/0000950170-24-125940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024125940/lxeo-20241111.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer